天大药业(00455.HK)中期股东应占亏损扩大至3350万港元

Group 1 - The company reported revenue of HKD 136.6 million for the six months ending June 30, 2025, compared to HKD 156.1 million for the same period in 2024 [1] - The loss attributable to shareholders increased from HKD 27.2 million in the previous interim period to HKD 33.5 million in the current interim period [1] - The board of directors decided not to declare an interim dividend for the six months ending June 30, 2025, consistent with the previous year [1]